The present study takes advantage of the identification of the SCLC‐A and SCLC‐N subgroups of SCLC cells which overexpress ASCL1 and NEUROD1 transcriptional activators, respectively, in order to first study their transcriptional programs and second to molecularly analyze the effect of the marine‐derived alkaloid lurbinectedin, that has proven clinically meaningful effects in metastatic SCLC (Singh et al, 2021). The gene discussed is NEUROD1; the disease is small cell lung carcinoma.